Shield Therapeutics Takeover Rumours (STX)

Skcots - "If that happens it goes to 6 to 8p depending on highest price in the proceeding year" Wrong. A delisting to take the company private and a takeover by buying out the other shareholders are not the same. The AIM is currently a graveyard of delisted companies claiming lack of liquidity and the company/shareholders can better be served by private investment. Furthermore if they did go for a full takeover they only have to hang on until October 2025 to offer you 3p. Just be careful here for it appears to me that's exactly the direction this stock is going in.

AOP can presumably help get STX over the debt hurdles even by buying the product wholesale, and selling it on again. There is a risk that AOP will takeover STX at a low price once the debt is resolved. An investment in AOP may be one way of profiting from STX success long term - but its a private company based in Austria.

Is this being prepped for a cheap takeover.

We got a business update on 21/11/24 with October 24 data. They also said “ The Company is engaged with The Panel on Takeovers and Mergers (the "Takeover Panel") to seek a waiver from the obligation of AOP Health to make an offer under Rule 9 of the Takeover Code and expects to convene a meeting of Shield's shareholders (the "General Meeting") before the end of 2024.â€￾ I would expect another business update around 21/12 with some November prescription data snd a date for the GM in mid Jan 25 as they must give 21 days notice.

21/11/24 RNS AOP Health subscription On 29 October 2024 the Company announced that it had entered into a non-binding term sheet with AOP Health International Management AG ("AOP Health") for the potential provision of $10 million of new equity. The Company is engaged with The Panel on Takeovers and Mergers (the "Takeover Panel") to seek a waiver from the obligation of AOP Health to make an offer under Rule 9 of the Takeover Code and expects to convene a meeting of Shield's shareholders (the "General Meeting") before the end of 2024. I wonder if “conveneâ€￾ means announcing the date of the meeting (21 days notice needed)? An RNS scheduling a GM mid Jan 25 along with November update might give everybody food for thought.

YE24 to target $35.5m should just breach running costs. YE22 was 0.1m US sales so 70+ gain! Their spoof target sales figure for YE24 was 184k and looks to be coming in about 155k+! These are facts! That said if AOP pursue takeover I will 100% vote for that as that board and last CEO are peas from same pod.

“The Company is engaged with The Panel on Takeovers and Mergers (the "Takeover Panel") to seek a waiver from the obligation of AOP Health to make an offer under Rule 9 of the Takeover Code and expects to convene a meeting of Shield's shareholders (the "General Meeting") before the end of 2024.â€￾ 21 days notice required usually and would have to be pre Xmas. So if this is true then only a couple of weeks for the notice.

patt - "But rest assured, only SWK have security. Not AOP." Yes having studied the finals again I agree. However that AOP is driving the share price down to takeover the company on the cheap I still maintain. And lets not forget STX has already rejected one offer from AOP. RNS 04/05/2023 - "The Mandatory Offer Price of 6.20 pence per Shield Share is equal to the highest price at which AOP or its concert parties have acquired Shield Shares over the 12 months prior to the date of this Announcement." "The Recommending Shield Directors are recommending Shield Shareholders do not accept the Mandatory Offer, but do not view the Mandatory Offer as being hostile." I'm doing some research on SWK and AOP to see if there is a link as they both appear to be in the same line of business similar to Bergen and New Tech if you know what I mean.

Funding at 4p is certainly better than & takeover by AOP at 2.5p & we are still in the game.Disappointing that there has been clearly large volume selling ahead of the 4p raise ,yet again - which is a disgrace-& illegal- not the Regulators will take action. $11.5mill revenue in Q4 is positive as it infers FY25 revenues of over $50mill-assuming we achieve modest quarterly growth in FY25 + revenues from Canada should start along with South Korea ( hopefully ) Could have been much worse & lets see what Batman & Robin have to say on Thursday & whether they will back up their expected confidence with actual share buying.